TY - JOUR
T1 - Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research
T2 - an interdisciplinary perspective
AU - Ramessur, Ravi
AU - Dand, Nick
AU - Langan, Sinéad M.
AU - Saklatvala, Jake
AU - Fritzsche, Marie-Christine
AU - Holland, Suzi
AU - Arents, Bernd W. M.
AU - McAteer, Helen
AU - Proctor, Andrew
AU - McMahon, David
AU - Greenwood, Michelle
AU - Buyx, Alena M.
AU - Messer, Tamara
AU - Weiler, Nina
AU - Hicks, Alexandra
AU - Hecht, Peter
AU - Weidinger, Stephan
AU - Ndlovu, Matladi N.
AU - Chengliang, Dai
AU - Hübenthal, Matthias
AU - Egeberg, Alexander
AU - Paternoster, Lavinia
AU - Skov, Lone
AU - de Jong, Elke M. G. J.
AU - Middelkamp-Hup, Maritza A.
AU - Mahil, Satveer K.
AU - Barker, Jonathan N.
AU - Flohr, Carsten
AU - the BIOMAP consortium
AU - Brown, Sara J.
AU - Smith, Catherine H.
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - More severe atopic dermatitis and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) consortium (a large-scale European, interdisciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small-scale studies through to large multicentre registries), clinical trials, electronic health records and large-scale population-based biobanks. We map all dataset disease severity instruments and measures to three key domains (symptoms, inflammatory activity and disease course), and describe important codependencies and relationships across variables and domains. We prioritize definitions for more severe disease with reference to international consensus, reference standards and/or expert opinion. Key factors to consider when analysing datasets across these diverse study types include explicit early consideration of biomarker purpose and clinical context, candidate biomarkers associated with disease severity at a particular point in time and over time and how they are related, taking the stage of biomarker development into account when selecting disease severity measures for analyses, and validating biomarker associations with disease severity outcomes using both physician- and patient-reported measures and across domains. The outputs from this exercise will ensure coherence and focus across the BIOMAP consortium so that mechanistic insights and biomarkers are clinically relevant, patient-centric and more generalizable to current and future research efforts.
AB - More severe atopic dermatitis and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) consortium (a large-scale European, interdisciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small-scale studies through to large multicentre registries), clinical trials, electronic health records and large-scale population-based biobanks. We map all dataset disease severity instruments and measures to three key domains (symptoms, inflammatory activity and disease course), and describe important codependencies and relationships across variables and domains. We prioritize definitions for more severe disease with reference to international consensus, reference standards and/or expert opinion. Key factors to consider when analysing datasets across these diverse study types include explicit early consideration of biomarker purpose and clinical context, candidate biomarkers associated with disease severity at a particular point in time and over time and how they are related, taking the stage of biomarker development into account when selecting disease severity measures for analyses, and validating biomarker associations with disease severity outcomes using both physician- and patient-reported measures and across domains. The outputs from this exercise will ensure coherence and focus across the BIOMAP consortium so that mechanistic insights and biomarkers are clinically relevant, patient-centric and more generalizable to current and future research efforts.
UR - https://www.scopus.com/pages/publications/85193710893
U2 - 10.1093/bjd/ljae080
DO - 10.1093/bjd/ljae080
M3 - Review article
C2 - 38419411
SN - 0007-0963
VL - 191
SP - 14
EP - 23
JO - British journal of dermatology
JF - British journal of dermatology
IS - 1
ER -